Aurion Biotech Launches Vyznova® (neltependocel) in Japan for the Treatment of Bullous Keratopathy of the Cornea

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced the commercial launch of Vyznova® (generic name: neltependocel) in Japan, for the treatment of bullous keratopathy of the cornea. The Company believes this is the first approved cell therapy for the treatment of corneal endothelial disease; it has received both regulatory and reimbursement approval in Japan. Th